TRANSPEP
How to develop a cancer therapy
Project description
This project involves the validation of a novel peptide compound (MTP-NRP1) anti-tumor.
Why does Conectus invest in this project?
Conectus' financial investment will make it possible to carry out studies for the production of a GMP (Good Manufacturing Practice) quality peptide and to find the best combination of treatments to refine the market positioning of targeted cancer therapies.
At the origin of the project:
Dominique Bagnard, (Senior Lecturer - MN3T Laboratory (The Microenvironmental Niche in Tumorigenesis and Targeted Therapy)
Focus
Conectus is investing in this project: 304 290 €.
Duration: 18 months